U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2010
465
Substance Class Protein
Created
by admin
on Sat Dec 16 17:55:09 GMT 2023
Edited
by admin
on Sat Dec 16 17:55:09 GMT 2023
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG2
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
4EQZ6YO2HI
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
DENOSUMAB
EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
AMG-162
Code English
DENOSUMAB [EMA EPAR]
Common Name English
XGEVA
Brand Name English
IMMUNOGLOBULIN G2, ANTI-(HUMAN RANK LIGAND) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER
Common Name English
DENOSUMAB [MI]
Common Name English
IMMUNOGLOBULIN G2, ANTI-(HUMAN RANK LIGAND) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER
Common Name English
AMG162
Code English
DENOSUMAB [VANDF]
Common Name English
IMMUNOGLOBULIN G2, ANTI-(HUMAN OSTEOCLAST DIFFERENTIATION FACTOR) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULPHIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER
Common Name English
Denosumab [WHO-DD]
Common Name English
denosumab [INN]
Common Name English
DENOSUMAB [JAN]
Common Name English
PROLIA
Brand Name English
DENOSUMAB [USAN]
Common Name English
DENOSUMAB [MART.]
Common Name English
IMMUNOGLOBULIN G2, ANTI-(HUMAN OSTEOCLAST DIFFERENTIATION FACTOR) (HUMAN MONOCLONAL AMG162 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL AMG162 LIGHT CHAIN, DIMER
Common Name English
DENOSUMAB [PURPLE BOOK CDER]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C20401
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
EMA ASSESSMENT REPORTS XGEVA (AUTHORIZED: NEOPLASM METASTASIS)
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
FDA ORPHAN DRUG 324110
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
EMA ASSESSMENT REPORTS PROLIA (AUTHORIZED: OSTEOPOROSIS, POSTMENOPAUSAL)
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
FDA ORPHAN DRUG 798920
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
EMA ASSESSMENT REPORTS PROLIA (AUTHORIZED: BONE RESORPTION)
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
NCI_THESAURUS C129822
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
NDF-RT N0000187055
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
FDA ORPHAN DRUG 404213
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
LIVERTOX NBK548424
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
EMA ASSESSMENT REPORTS XGEVA (AUTHORIZED: FRACTURES, BONE)
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
WHO-VATC QM05BX04
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
WHO-ATC M05BX04
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
Code System Code Type Description
NDF-RT
N0000187054
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY RANK Ligand Blocking Activity [MoA]
CAS
615258-40-7
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
DRUG CENTRAL
4965
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
ChEMBL
CHEMBL1237023
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
IUPHAR
6886
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
EVMPD
SUB29173
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
FDA UNII
4EQZ6YO2HI
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
SMS_ID
100000090712
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
DRUG BANK
DB06643
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
LACTMED
Denosumab
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
USAN
QQ-76
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
RXCUI
993449
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY RxNorm
DAILYMED
4EQZ6YO2HI
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
INN
8653
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
NCI_THESAURUS
C61313
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
WIKIPEDIA
DENOSUMAB
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
MERCK INDEX
m4167
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY Merck Index
MESH
C494392
Created by admin on Sat Dec 16 17:55:10 GMT 2023 , Edited by admin on Sat Dec 16 17:55:10 GMT 2023
PRIMARY
From To
1_22 1_96
1_136 3_215
1_149 1_205
1_224 2_224
1_225 2_225
1_228 2_228
1_231 2_231
1_262 1_322
1_368 1_426
2_22 2_96
2_136 4_215
2_149 2_205
2_262 2_322
2_368 2_426
3_23 3_89
3_135 3_195
4_23 4_89
4_135 4_195
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_298
N 2_298
Related Record Type Details
TK-006
SUB_CONCEPT->SUBSTANCE
DENOSUMAB BIOSIMILAR (QL-1206)
BIOSIMILAR -> PARENT
DENOSUMAB BIOSIMILAR (QL-1206)
SUB_CONCEPT->SUBSTANCE
DENOSUMAB BIOSIMILAR (CT-P41)
BIOSIMILAR -> PARENT
DENOSUMAB BIOSIMILAR (HLX-14)
BIOSIMILAR -> PARENT
RANKL (SOLUBLE FORM)
TARGET -> INHIBITOR
TK-006
BIOSIMILAR -> PARENT
RANKL (MEMBRANE BOUND)
TARGET -> INHIBITOR
Denosumab is a fully human monoclonal antibody that binds to RANKL, preventing it from binding its receptor RANK, and thereby inhibiting formation, action, and survival of osteoclasts
DENOSUMAB BIOSIMILAR (HLX-14)
SUB_CONCEPT->SUBSTANCE
DENOSUMAB BIOSIMILAR (CT-P41)
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
DENOSUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Molecular Formula CHEMICAL
MOL_WEIGHT:FORMULA CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966